Key Points
- Hinge Health CFO James Budge sold 781 shares on May 20 at an average price of $55.34, for proceeds of about $43,221. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and Budge still holds 451,293 shares.
- The stock has been active recently, with Budge also selling shares on May 11 and March 23. Despite the insider sales, HNGE opened around $55.11 and has traded near its 52-week high of $62.18.
- Hinge Health reported strong quarterly results on May 5, beating EPS estimates with $0.45 per share and posting revenue of $182.31 million, up 47.2% year over year. Analysts remain broadly bullish, with an average price target of $67.40.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CFO James Budge sold 781 shares of the business's stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $55.34, for a total transaction of $43,220.54. Following the completion of the sale, the chief financial officer directly owned 451,293 shares of the company's stock, valued at $24,974,554.62. This represents a 0.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Budge also recently made the following trade(s):
- On Monday, May 11th, James Budge sold 5,906 shares of Hinge Health stock. The stock was sold at an average price of $54.82, for a total transaction of $323,766.92.
- On Monday, March 23rd, James Budge sold 11,006 shares of Hinge Health stock. The shares were sold at an average price of $42.26, for a total transaction of $465,113.56.
Hinge Health Trading Up 0.7%
Shares of HNGE stock opened at $55.11 on Friday. The stock has a market cap of $4.26 billion and a P/E ratio of -4.47. The stock has a 50 day simple moving average of $44.84 and a 200 day simple moving average of $44.35. Hinge Health Inc. has a 1 year low of $30.08 and a 1 year high of $62.18.
Hinge Health (NYSE:HNGE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.33. The firm had revenue of $182.31 million for the quarter. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.Hinge Health's revenue was up 47.2% on a year-over-year basis. During the same quarter last year, the business earned $1.30 EPS. Analysts forecast that Hinge Health Inc. will post 1.21 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BIT Capital GmbH boosted its stake in shares of Hinge Health by 79.3% in the 4th quarter. BIT Capital GmbH now owns 3,316,101 shares of the company's stock valued at $154,033,000 after purchasing an additional 1,466,577 shares in the last quarter. Vanguard Group Inc. increased its position in Hinge Health by 110.5% during the 4th quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company's stock worth $121,027,000 after purchasing an additional 1,367,693 shares in the last quarter. Tiger Global Management LLC increased its position in Hinge Health by 227.1% during the 4th quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company's stock worth $83,877,000 after purchasing an additional 1,253,743 shares in the last quarter. Marshall Wace LLP bought a new position in Hinge Health in the 4th quarter valued at approximately $54,469,000. Finally, Millennium Management LLC lifted its stake in Hinge Health by 225.0% in the 4th quarter. Millennium Management LLC now owns 1,479,642 shares of the company's stock valued at $68,729,000 after purchasing an additional 1,024,317 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on HNGE shares. Truist Financial set a $79.00 price target on Hinge Health in a research note on Wednesday, May 6th. Zacks Research raised shares of Hinge Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, May 13th. Raymond James Financial restated an "outperform" rating and issued a $70.00 target price on shares of Hinge Health in a research report on Wednesday, May 6th. Freedom Capital raised shares of Hinge Health to a "strong-buy" rating in a report on Thursday, January 22nd. Finally, Needham & Company LLC increased their price target on shares of Hinge Health from $59.00 to $63.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $67.40.
Get Our Latest Stock Report on Hinge Health
About Hinge Health
(
Get Free Report)
Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.
Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
